POTENTIAL USE OF GLP-1 RECEPTOR AGONISTS IN THE MANAGEMENT OF CHRONIC PAIN SYNDROMES: ANTI-INFLAMMATORY AND NEUROPROTECTIVE PERSPECTIVES
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6275Keywords:
GLP-1 Receptor Agonists, Chronic Pain, Neuropathic Pain, Neuroinflammation, Migraine, Fibromyalgia, Osteoarthritis, NeuroprotectionAbstract
Chronic pain syndromes remain a major clinical and public health challenge because of their multifactorial pathophysiology, frequent refractoriness to standard treatment, and marked effects on quality of life, disability, sleep, psychological well-being, and work capacity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for type 2 diabetes and obesity, have recently attracted growing interest beyond metabolic medicine because their biological actions appear to extend to anti-inflammatory, antioxidative, neuroprotective, and cytoprotective pathways. These pleiotropic properties are potentially relevant to chronic pain, which is increasingly understood as a condition sustained not only by nociceptive input but also by neuroinflammation, glial activation, oxidative stress, maladaptive neuronal plasticity, mitochondrial dysfunction, and metabolic dysregulation.
This narrative review examines the current biological and translational rationale for GLP-1RAs in chronic pain syndromes, with emphasis on neuropathic pain, diabetic peripheral neuropathy, migraine-related central sensitization, fibromyalgia-related mechanisms, osteoarthritis-associated pain, inflammatory musculoskeletal pain, and visceral pain. Available evidence suggests that GLP-1 receptor activation may modulate several processes implicated in pain chronification, including pro-inflammatory cytokine signaling, microglial activation, oxidative stress, mitochondrial dysfunction, and impaired neuronal resilience. Experimental studies also indicate possible involvement of IL-10-mediated anti-inflammatory signaling, AMPK/NF-kappaB pathway modulation, and broader neuroimmune regulation.
However, the current evidence base remains heterogeneous and is still dominated by preclinical studies, mechanistic reviews, and early observational data. Human evidence in non-diabetic chronic pain populations remains limited, and in many settings it is difficult to separate direct analgesic effects from indirect benefits related to weight loss, improved glycemic control, reduced systemic inflammation, or improved function. At present, GLP-1RAs should therefore be regarded as biologically plausible and clinically promising, but still investigational, candidates in chronic pain management rather than established analgesic therapies. Further translational work and adequately powered prospective clinical studies are required to clarify efficacy, safety, mechanism-specific effects, and phenotype-specific patient selection.
References
Alfaro-Martinez, J. J., Lopez-Gomez, J. J., Ahmed, S. S., Motallebzadeh, R., McVeigh, N. M., Parekh, S., McVeigh, C. M., Kaye, A. D., Thaker, J. S., Yong, R. J., Kaye, A. M., Urits, I., & Viswanath, O. (2026). The potential indirect impact of GLP-1 receptor agonists in the management of fibromyalgia. *Journal of Clinical Medicine, 15*(9), 3330.
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., Loretelli, C., D'Addio, F., Berra, C., Ben Nasr, M., Zuccotti, G. V., & Fiorina, P. (2022). The anti-inflammatory and immunological properties of GLP-1 receptor agonists. *Pharmacological Research, 182*, 106320. https://doi.org/10.1016/j.phrs.2022.106320
Bilgin, E., Venerito, V., & Bogdanos, D. P. (2025). Glucagon-like peptide-1 receptor agonists in rheumatology: A review of current evidence and future directions. *Autoimmunity Reviews, 24*(9), 103864. https://doi.org/10.1016/j.autrev.2025.103864
Bliddal, H., Bays, H. E., Czernichow, S., Deanfield, J., Flint, A., Gibson, S., Haluzik, M., Jensen, T. J., Kamiya, K., Lau, D. C. W., le Roux, C. W., McGowan, B. M., O'Neil, P. M., Rubino, D. M., Wiese, R. J., & Gudbergsen, H. (2024). Once-weekly semaglutide in persons with obesity and knee osteoarthritis. *The New England Journal of Medicine, 390*(15), 1394-1408.
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., Loretelli, C., D'Addio, F., Berra, C., Ben Nasr, M., Zuccotti, G. V., & Fiorina, P. (2022). The anti-inflammatory and immunological properties of GLP-1 receptor agonists. *Pharmacological Research, 182*, 106320. https://doi.org/10.1016/j.phrs.2022.106320
Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. *Cell Metabolism, 27*(4), 740-756. https://doi.org/10.1016/j.cmet.2018.03.001
He, Y., Xu, B., Zhang, M., Chen, D., Wu, S., Gao, J., Liu, Y., Zhang, Z., Kuang, J., & Fang, Q. (2025). Advances in GLP-1 receptor agonists for pain treatment and their future potential. *The Journal of Headache and Pain, 26*(1), 46. https://doi.org/10.1186/s10194-025-01979-4
Holst, J. J. (2019). The physiology of glucagon-like peptide 1. *Physiological Reviews, 99*(3), 1405-1430. https://doi.org/10.1152/physrev.00034.2018
Jing, F., Zeng, Y., Yu, Q.-L., Fu, C.-J., Zhang, F., & Tang, Y. (2025). The role of GLP-1 receptor in pain disorders and its pharmacological properties. *European Journal of Pharmacology*, 178345. https://doi.org/10.1016/j.ejphar.2025.178345
Jing, F., Zou, Q., Pu, Y., Wang, Y., & Tang, Y. (2023). GLP-1R agonist liraglutide attenuates pain hypersensitivity by stimulating IL-10 release in a nitroglycerin-induced chronic migraine mouse model. *Neuroscience Letters, 812*, 137397. https://doi.org/10.1016/j.neulet.2023.137397
Jing, F., Zou, Q., Wang, Y., Cai, Z., & Tang, Y. (2021). Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation. *The Journal of Headache and Pain, 22*(1), 86. https://doi.org/10.1186/s10194-021-01302-x
Lu, C., Xu, C., & Yang, J. (2024). The beneficial effects of GLP-1 receptor agonists other than their anti-diabetic and anti-obesity properties. *Medicina, 61*(1), 17. https://doi.org/10.3390/medicina61010017
Ma, L., Ju, P., Wang, W., Wei, J., Wang, W., Zhao, M., Ahmad, K. A., Wang, Y., & Chen, J. (2021). Microglial activation of GLP-1R signaling in neuropathic pain promotes gene expression adaption involved in inflammatory responses. *Neural Plasticity, 2021*, 9923537. https://doi.org/10.1155/2021/9923537
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., Seeley, R. J., Stemmer, K., Tang-Christensen, M., Woods, S. C., DiMarchi, R. D., & Tschöp, M. H. (2019). Glucagon-like peptide 1 (GLP-1). *Molecular Metabolism, 30*, 72-130. https://doi.org/10.1016/j.molmet.2019.09.010
Nauck, M. A., & Quast, D. R. (2021). Cardiovascular safety and benefits of glucagon-like peptide-1 receptor agonists. *The Lancet Diabetes & Endocrinology, 9*(10), 653-662. https://doi.org/10.1016/S2213-8587(21)00169-0
Si, J., Yu, K., Hao, J., Wang, J., & Zhang, L. (2025). The therapeutic effects and mechanisms of glucagon-like peptide-1 receptor agonists in neurocognitive disorders. *Therapeutic Advances in Chronic Disease, 16*, 20406223251332035. https://doi.org/10.1177/20406223251332035
Wu, X., Li, Y., Chen, H., Zhao, M., Zhang, J., & Liu, Q. (2026). Glucagon-like peptide-1 receptor agonists in rheumatoid arthritis: A scoping review of metabolic, anti-inflammatory, and cardioprotective effects. *Journal of Personalized Medicine, 16*(6), 284. https://doi.org/10.3390/jpm16060284
Zhang, L.-Q., Zhang, W., Li, T., Yang, T., Yuan, X., Zhou, Y., Zou, Q., Yang, H., Gao, F., Tian, Y., Mei, W., & Tian, X.-B. (2021). GLP-1R activation ameliorated novel-object recognition memory dysfunction via regulating hippocampal AMPK/NF-kappaB pathway in neuropathic pain mice. *Neurobiology of Learning and Memory, 182*, 107463. https://doi.org/10.1016/j.nlm.2021.107463
Zhang, L., Zhang, W., & Tian, X. (2021). The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases. *International Journal of Neuroscience, 133*(5), 473-491. https://doi.org/10.1080/00207454.2021.1924707
Zheng, J., Lu, Y., Chen, W., Li, F., Chen, G., Wang, X., & Zhang, Y. (2024). Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy. *Signal Transduction and Targeted Therapy, 9*, 88. https://doi.org/10.1038/s41392-024-01745-9
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Dominika Krupnik, Wiktoria Skowron, Mateusz Skowron, Monika Łapot, Krzysztof Hober, Wiktoria Bzdak, Patrycja Szwemińska, Joanna Górak, Wojciech Neumann
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
